Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor-induced bullous pemphigoid.

Competing Interests: Conflicts of interest Arash Mostaghimi receives personal fees from Pfizer, hims, Digital Diagnostics, Concert, Lilly, AbbVie, and Bioniz; he is also an associate editor of JAMA Dermatology. Steven T. Chen received honoraria for serving on a social media advisory board for Pfizer and Novartis outside the submitted work. Nicole R. LeBoeuf is a consultant and has received honoraria from Bayer, Seattle Genetics, Sanofi, Silverback, and Synox Therapeutics outside the submitted work. The remaining authors (Said, Talia, Wei, Semenov, and Giobbie-Hurder) have no potential conflicts of interest involving this research or outside the submitted work.